Hollie Franklin, Author at Drugs in Context

Manidipine: an antihypertensive drug with positive effects on metabolic parameters and adrenergic tone in patients with diabetes

Margarita SaizSatjes, Francisco Javier Martinez-Martin

Article Type

Review

Published

03 Jan 2018

Examines combining a dihydropyridine calcium channel blocker with a renin-angiotensin-aldosterone system inhibitor for the treatment of diabetes

Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain

Darío Antolín-Amerigo, Isabel A Tabar, Maria del Mar Fernández-Nieto, Anna M Callejo-Melgosa, Francisco J Muñoz-Bellido, José C Martínez-Alonso, Jorge D Méndez-Alcalde, Marta Reche, Ana Rodríguez-Trabado, Ana Rosado-Ingelmo, Alicia Alonso-Gómez, Rosa Blanco-González, José A Alvarez-Fernandez, Isabel Botella, Ana Valls, Mercedes Cimarra, Carlos Blanco

Article Type

Original Research

Published

06 Oct 2017

This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing five-grass pollen tablet treatment.

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy

Constantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, Frank Garcia, Peter D Montan, Eliscer Guzman

Article Type

Review

Published

22 Nov 2017

This review aims to present and discuss the current clinical and scientific data pertaining to lipid-lowering interventions targeting PCSK9.

Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review

Rajesh R Tampi, Corey Hassell, Pallavi Joshi, Deena J Tampi

Article Type

Review

Published

22 Nov 2017

This review assesses the efficacy and tolerability of analgesics in reducing behavioral and psychological symptoms of dementia among older adults from published randomized controlled trials.

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

Neon Brooks, Mario Campone, Silvia Paddock, Scott Shortenhaus, David Grainger, Jacqueline Zummo, Samuel Thomas, Rose Li

Article Type

Original Research

Published

15 Nov 2017

This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.